Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 6:42 PM ET

Biotechnology

Company Overview of Capricor Therapeutics, Inc.

Company Overview

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

8840 Wilshire Boulevard

2nd Floor

Beverly Hills, CA 90211

United States

Founded in 2005

28 Employees

Phone:

310-358-3200

Key Executives for Capricor Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and Secretary
Age: 61
Total Annual Compensation: $243.8K
Vice President of Medical Affairs
Age: 52
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

Capricor Therapeutics, Inc. Key Developments

Capricor Gets FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. announced that it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cardiosphere-derived cells (CDCs, also known as CAP-1002, are a potential therapeutic approach for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. The cells have been shown to promote cardiomyogenesis and angiogenesis, while inhibiting oxidative stress, inflammation and fibrosis in preclinical studies. Pre-clinical data presented at the American Heart Association's annual meeting in November 2014 demonstrated that cardiac function and exercise capacity improved in CDC-treated mdx mice, accompanied by attenuation of inflammation, improved mitochondrial function and a reduction in collagen content and fibrosis in CDC-treated mdx hearts. The findings raise the possibility that CDCs may be useful therapeutically for heart failure in patients with Duchenne muscular dystrophy.

Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure

Capricor Therapeutics, Inc. has completed enrollment of the initial phase of its DYNAMIC clinical trial for the treatment of advanced heart failure. DYNAMIC is a trial of CAP-1002, Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy in clinical development for the treatment of advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below. Fourteen patients were enrolled and were administered CAP-1002 down all three coronary arteries (triple vessel infusion using standard intracoronary catheter). DYNAMIC marks the first time that CAP-1002 has been used clinically in patients with severe, global left ventricular dysfunction. The triple vessel infusion is designed to deliver cells to wide areas of myocardium since patients with advanced heart failure have significant fibrosis in all areas of the left ventricle. Safety, as well as a variety of exploratory 6 and 12 month efficacy endpoints including ejection fraction, ventricular volumes and a six-minute walk test, will be evaluated.

Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

Capricor Therapeutics, Inc. announced that it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for the outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications. The trial completed enrollment of 14 patients. Patients received up to eight consecutive days of increasing doses of Cenderitide by continuous subcutaneous infusion using Insulet's OmniPod® drug delivery system. The trial assessed the safety, tolerability, pharmacokinetic profile and pharmacodynamic response to increasing dose levels of open-label Cenderitide administered in a stepwise fashion, with each patient receiving the entire range of doses.

Similar Private Companies By Industry

Company Name Region
Sub-Micro, Inc. United States
Pan Pacific Pharmaceuticals, Inc. United States
Revimmune, Inc United States
Millennium Life Sciences, Inc. United States
Open Monoclonal Technology, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 3, 2015
--
Private Placement
January 9, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Capricor Therapeutics, Inc., please visit www.capricor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.